Skip to main content
. Author manuscript; available in PMC: 2016 Sep 10.
Published in final edited form as: Cell. 2015 Sep 10;162(6):1242–1256. doi: 10.1016/j.cell.2015.08.052

Figure 6. Anti-PD-1 blocking antibody inhibits human melanoma xenograft growth in immunocompromised mice.

Figure 6

(A) Kinetics (mean±s.d.) of clinical melanoma xenograft growth in NSG mice treated with anti-human PD-1 or isotype control antibody (patient A, n=7 each; patient B, n=5 vs. 4; patient C: n=10 each). (B) Tumor growth kinetics (mean±s.d.) and (C) representative secondary antibody staining (size bars, 50μm) of mouse anti-human PD-1 vs. isotype control antibody-treated human A375 (n=14 each), C8161 (n=14 each), or G3361 melanoma xenografts (n=16 vs. 12) or of (D) human PDCD1-OE vs. vector control-transduced C8161 xenografts in NSG mice (n=10 each). Immunohistochemical images illustrate binding of in vivo-administered mouse anti-human PD-1 blocking but not isotype control antibody to the respective human melanoma xenograft (size bars, 50μm). (E) Mean number of tumor spheres±s.e.m. and (F) flow cytometric assessment of cell death (percent AnnexinV+/7AAD+ cells, mean±s.e.m. (left) and representative flow cytometry plots (right) of anti-PD-1- vs. isotype control mAb-treated human A375, C8161, and G3361 melanoma cultures. (H) Immunoblot analysis (representative of n=3 independent experiments) of phosphorylated (p) and total ribosomal protein S6, AKT, and ERK in G3361 cultures concurrently treated with PD-L1 Ig vs. control Ig and/or anti-PD-1- vs. isotype control mAb (NS: not significant, *P<0.05, **P<0.01, ***P<0.001).